Madrigal says MAESTRO-NASH analysis shows Rezdiffra efficacy consistent across MASH genetic risk variants
MDGL•Madrigal said a secondary analysis of its Phase 3 MAESTRO-NASH trial found Rezdiffra benefits on liver disease measures were broadly consistent across common genetic risk variants. The analysis included 738 participants with genetic testing and paired biopsies.
1. Trial analysis findings
Madrigal reported the secondary analysis in the Journal of Hepatology. The findings covered 738 participants with genetic testing and paired biopsies, limiting conclusions about rarer variants and small subgroups.
